Patent intelligence · US
US 12427111
Lipid nanoparticles
Lipid nanoparticles
Patent details — US 12427111
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 30, 2025
- Expiration
- Sep 25, 2045
- Applicant
- CodeBridgeBio Inc.
- Claims
- 13
- CPC classes
- A61K, A61K31/7105, A61K31/711, A61K9/1271
Quick answer
US 12427111 (Lipid nanoparticles) is held by CodeBridgeBio Inc.. Status: granted. Granted Sep 30, 2025. Expires Sep 25, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CodeBridgeBio Inc.
- Grant date
- Expiration
- Claims
- 13
- CPC classes
- A61K, A61K31/7105, A61K31/711, A61K9/1271, A61K9/5123
Frequently asked questions
What is US patent 12427111?
US 12427111 (Lipid nanoparticles) is held by CodeBridgeBio Inc.. Status: granted. Granted Sep 30, 2025. Expires Sep 25, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12427111?
CodeBridgeBio Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.
When does US 12427111 expire?
Our index shows an expiration date of Sep 25, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.